Need immediate assistance? Call 1 800.927.5900 or Contact Us
Demand for drug delivery products in the US will rise 6.1 percent yearly to $251 billion in 2019. Parenteral products will grow the fastest, driven by monoclonal antibodies and polymer-encapsulated medicines. Hormones and central nervous system agents will lead gains by application. Pen injectors and retractable prefillable syringes will pace devices.
This study analyzes the $187 billion US drug delivery system industry. It presents historical demand data (2004, 2009 and 2014) and forecasts (2019 and 2024) by product (e.g., oral, parenteral, inhalation, transdermal, implantable) and application (e.g., central nervous system, hormones, respiratory, anti-infective, cardiovascular, gastrointestinal, nutritional).
The study also considers market environment factors, details industry structure, evaluates company market share, and profiles 30 industry players, including Gilead Sciences, Roche, and Johnson & Johnson.
Add This Study To Your Cart.
Register, Checkout and
Verify Payment.
Your Report Is Available.
Table of Contents
INTRODUCTION
EXECUTIVE SUMMARY
MARKET ENVIRONMENT
General
Economic Factors
Demographic Patterns
Healthcare Trends
Health Insurance Reforms
Medical Conditions
Acute Conditions
Chronic Conditions
National Health Expenditures
Spending Categories
Funding Sources
Medical Providers
Hospitals
Outpatient Facilities
Physicians
Skilled Nursing Homes
Patient Activity
Hospital Activity
Outpatient Activity
Surgical Procedures
Pharmaceutical Industry Overview
Regulation
Research & Development
Product Demand
Therapeutic Groups
Dosage Formulations
Regulatory Classes
Commercial Status
DRUG DELIVERY PRODUCT OVERVIEW
General
Types of Drug Delivery Products
Historical Market Trends
US Trade
International Markets
ORAL DRUG DELIVERY PRODUCTS
General
Controlled-Release Formulations
Film-Coated Formulations
Diffusion Formulations
Reservoir Formulations
Chewable Tablets
Orally Disintegrating Tablets
Nanoparticulate Formulations
Transmucosal Formulations
PARENTERAL DRUG DELIVERY PRODUCTS
General
Therapeutic Monoclonal Antibodies
Technology
Products
HUMIRA (adalimumab)
REMICADE (infliximab)
RITUXAN (rituximab)
AVASTIN (bevacizumab)
HERCEPTIN (trastuzumab)
LUCENTIS (ranibizumab)
STELARA (ustekinumab)
XOLAIR (omalizumab)
TYSABRI (natalizumab)
Other Monoclonal Antibodies
New Products
Developmental Products
Encapsulated Parenteral Formulations
Polymer-Protected Formulations
PEG-Based Parenteral Therapies
Other Polymer-Protected Parenteral Therapies
Developmental Activities
Liposomes
Technology
Marketed Products
Developmental Activities
Infusion Products
IV Administration Sets
Premixed IV Solutions
Infusion Pumps
Other Infusion Products
Enteral Feeding Supplies
IV Accessories
Parenteral Devices
Prefillable Syringes
Injectors
Cartridge Systems
Hypodermic Syringes
IV Catheters
Other Parenteral Devices
OTHER DRUG DELIVERY PRODUCTS
General
Inhalation Drug Delivery Products
Dry Powder Formulations
Metered Dose Formulations
Transdermal Drug Delivery Products
Transdermal Technologies
Central Nervous System Agents
Hormones & Related Agents
Cardiovascular Agents
Other Transdermal Patches
Implantable Drug Delivery Products
Drug Inserts
Drug-Eluting Stents
Other Implantable Drug Delivery Products
Brachytherapy Products
Implantable Drug Pumps
APPLICATIONS
General
Central Nervous System Agents
Controlled-Release Formulations
Other Oral Drug Delivery Products
Transdermal Formulations
Monoclonal Antibodies & Polymer Encapsulated Therapies
Liposomes
Other Drug Delivery Products
Hormones & Related Agents
Anticancer Monoclonal Antibodies
Encapsulated Polymers
Liposomes
Insulin Pen Injectors
Controlled-Release & Other Oral Drug Delivery Products
Transdermal Hormones & Related Agents
Other Drug Delivery Products
Respiratory Agents
Dry Powder Inhalers
Metered Dose Inhalers
Monoclonal Antibodies
Anti-Infective Agents
Cardiovascular Agents
Controlled-Release Formulations
Monoclonal Antibodies
Drug-Eluting Stents
Transdermal Patches
Gastrointestinal Agents
Nutritional Agents
Other Pharmaceuticals
INDUSTRY STRUCTURE
General
Market Share
Dosage Formulations
Devices
Competitive Strategies
Mergers & Acquisitions
Licensing & Related Agreements
Marketing & Distribution
Manufacturing
Company Profiles
Abbott Laboratories
AbbVie Incorporated
Actavis, see Allergan
Adare Pharmaceuticals Incorporated
Allergan plc
Amgen Incorporated
Animas, see Johnson & Johnson
Aptalis Pharma, see Allergan
Aptalis Pharmaceutical Technologies, see Adare Pharmaceuticals
AptarGroup Incorporated
AstraZeneca plc
Baxter International Incorporated
Becton, Dickinson, and Company
Boehringer Ingelheim GmbH
Braun (B.) Melsungen AG
Bristol-Myers Squibb Company
CareFusion, see Becton, Dickinson
Evonik Industries AG
Forest Laboratories, see Allergan
Genentech, see Roche Holding
Genzyme, see Sanofi
Gerresheimer AG
Gilead Sciences Incorporated
GlaxoSmithKline plc
Hospira, see Pfizer
ImClone Systems, see Lilly (Eli)
Janssen Pharmaceuticals, see Johnson & Johnson
Johnson & Johnson
Lilly (Eli) and Company
MedImmune, see AstraZeneca
Merck & Company Incorporated
Nitto Denko Corporation
Novartis AG
Novo Nordisk A/S
Pfizer Incorporated
Regeneron Pharmaceuticals, see Sanofi
Roche Holding Limited
Sanofi
Teva Pharmaceutical Industries Limited
3M Company
Unilife Corporation
Vetter Pharma International GmbH
West Pharmaceutical Services Incorporated
Additional Companies in the Drug Delivery Product Market
List of Tables
EXECUTIVE SUMMARY
Summary Table
MARKET ENVIRONMENT
Macroeconomic Indicators
Resident Population by Age Group
Health Insurance Coverage of the US Population, 2004-2014
Acute Conditions by Type
Chronic Conditions by Type
National Health Expenditures by Spending Category
National Health Expenditures by Funding Source
Medical Providers by Type
Patient Activity by Type
Pharmaceutical Demand by Therapeutic Class
Pharmaceutical Demand by Dosage Formulation
Pharmaceutical Demand by Regulatory Classification
Pharmaceutical Demand by Patent Status
DRUG DELIVERY PRODUCT OVERVIEW
Drug Delivery Product Demand by Type
Drug Delivery Product Demand Patterns, 2004-2014
US Trade in Drug Delivery Products
World Drug Delivery Product Demand by Region
ORAL DRUG DELIVERY PRODUCTS
Oral Drug Delivery Product Demand by Type
Controlled-Release Oral Drug Delivery Product Demand
Film-Coated Oral Drug Delivery Product Demand
Diffusion Oral Drug Delivery Product Demand
Reservoir Oral Drug Delivery Product Demand
Chewable Tablet Product Demand by Therapeutic Class
Orally Disintegrating Tablet Demand by Therapeutic Class
Oral Nanoparticulate Drug Delivery Product Demand by Therapeutic Class
Transmucosal Drug Delivery Product Demand by Therapeutic Class
PARENTERAL DRUG DELIVERY PRODUCTS
Parenteral Drug Delivery Product Demand by Type
Therapeutic Monoclonal Antibody Demand by Therapeutic Class
Encapsulated Parenteral Product Demand by Typ & Therapeutic Class
Infusion Product Demand by Type
Parenteral Device Demand by Type
OTHER DRUG DELIVERY PRODUCTS
Other Drug Delivery Product Demand by Type
Inhalation Drug Delivery Product Demand by Type
Dry Powder Inhaler Demand
Metered Dose Inhaler Demand
Transdermal Drug Delivery Product Demand by Therapeutic Class
Implantable Drug Delivery Product Demand by Type
Drug Insert Demand by Therapeutic Class
Drug-Eluting Stent Demand
Other Implantable Drug Delivery Product Demand by Type
APPLICATIONS
Drug Delivery Product Demand by Therapeutic Class
Central Nervous System Drug Delivery Product Demand by Type
Hormone & Related Drug Delivery Product Demand by Type
Respiratory Drug Delivery Product Demand by Type
Anti-Infective Drug Delivery Product Demand by Type
Cardiovascular Drug Delivery Product Demand by Type
Gastrointestinal Drug Delivery Product Demand by Type
Nutritional Preparation Delivery Product Demand by Type
Other Application Drug Delivery Product Demand by Type
INDUSTRY STRUCTURE
US Drug Delivery Product Sales by Company, 2014
Selected Acquisitions & Divestitures
Selected Cooperative Agreements
© by The Freedonia Group, Inc.